TITLE

Oral fingolimod was more effective than placebo for relapsing-remitting multiple sclerosis

AUTHOR(S)
Hughes, James
PUB. DATE
May 2010
SOURCE
ACP Journal Club;5/18/2010, Vol. 152 Issue 5, p6
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents a study that discusses the effective use of drugs such as oral fingolimod and placebo in patients with relapsing-remitting multiple sclerosis (MS). As stated, doses of oral fingolimod and placebo were given to thousands of patients during the clinical trail of MS. However, it concludes that doses of oral fingolimod are more effective than placebo but its higher dose could release serious adverse events.
ACCESSION #
51696574

 

Related Articles

  • Oral cladribine was more effective than placebo for relapsing-remitting multiple sclerosis. Hughes, James // ACP Journal Club;5/18/2010, Vol. 152 Issue 5, p7 

    The article presents a study that discusses the effective use of drugs such as oral cladribine and placebo in patients with relapsing-remitting multiple sclerosis (MS). As stated, doses of oral cladribine and placebo were given to thousands of patients during the clinical trail of MS. However,...

  • Untitled.  // BioWorld Today;12/10/2009, Vol. 20 Issue 237, p3 

    The article reports on the Phase III STAR trial of Zenvia versus placebo in pseudobulbar affect (PBA) secondary to amyotrophic lateral sclerosis (ALS) or multiple sclerosis being conducted by Avanir Pharmaceuticals Inc. According to additional data from the subset of ALS patients, both doses of...

  • Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study. Bar-Or, Amit; Gold, Ralf; Kappos, Ludwig; Arnold, Douglas; Giovannoni, Gavin; Selmaj, Krzysztof; O'Gorman, John; Stephan, Monica; Dawson, Katherine // Journal of Neurology;Sep2013, Vol. 260 Issue 9, p2297 

    In the double-blind, placebo-controlled, Phase 3 DEFINE study in patients with relapsing-remitting multiple sclerosis, oral BG-12 (dimethyl fumarate) significantly reduced the proportion of patients relapsed (primary endpoint), the annualized relapse rate (ARR), and confirmed disability...

  • BACLOFEN. GRIFFITH, H. WINTER // Complete Guide to Prescription & Nonprescription Drugs 2012;2010, p164 

    The article presents information on baclofen, a muscle relaxant for multiple sclerosis, including its dosage, usage, adverse reactions, side effects, precautions when administering, and possible interaction with other drugs.

  • BACLOFEN.  // Complete Guide to Prescription & Nonprescription Drugs 2012;2007, p164 

    The article presents information on baclofen, a muscle relaxant used for the treatment of multiple sclerosis. The dosage and usage information is provided. The possible adverse reactions or side effects of the drug, warnings, and precautions are discussed. Possible interaction of the drug with...

  • BACLOFEN.  // Complete Guide to Prescription & Nonprescription Drugs 2012;2008, p164 

    The article presents information on baclofen, a muscle relaxant used for the treatment of multiple sclerosis. The dosage and usage information is provided. The possible adverse reactions or side effects of the drug, warnings, and precautions are discussed. Possible interaction of the drug with...

  • BACLOFEN. GRIFFITH, H. WINTER // Complete Guide to Prescription & Nonprescription Drugs 2012;2009, p164 

    The article presents information on baclofen, a drug used as a muscle relaxant for multiple sclerosis with brand names Kemstro and Lioresal, including dosage, usage, adverse reactions, side effects, precautions, and possible interaction with other drugs.

  • Improving functional outcomes in patients with multiple sclerosis.  // British Journal of Hospital Medicine (17508460);Nov2008, Vol. 69 Issue 11, p613 

    The article reports on the study concerning the effect of the drug Tysabri (natalizumab) in patients with multiple sclerosis. A post-hoc analysis has shown that the drug increases the chance of achieving sustained improvement in physical disability over 2 years compared to placebo. More...

  • PEGylated interferon beta-Ia in the treatment of multiple sclerosis - an update. Reuss, Reinhard // Biologics: Targets & Therapy;May2013, Vol. 7, p131 

    Current standard immunomodulatory therapy with interferons (IFNs) for relapsing-remitting multiple sclerosis (MS) exhibits proven, but limited, efficacy and increased side effects due to the need of frequent application of the drug. Therefore, there is a need for more effective and tolerable...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics